ORIC Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

$4.40
As of 07/01/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/24/2020
Outstanding shares:  39,478,212
Average volume:  457,814
Market cap:   $176,862,390
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BKVDFF7
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.69
PS ratio:   0.00
Return on equity:   -40.25%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy